ESR1 and male breast carcinoma: Endocrine therapy remains the cornerstone of systemic treatment in male breast cancer due to the overwhelmingly high prevalence of hormone receptor positivity, a pattern consistently observed across multiple studies including our own cohort, in which nearly 90% of evaluable patients were ER-positive.